Raphael Mohr

2.1k total citations
70 papers, 942 citations indexed

About

Raphael Mohr is a scholar working on Oncology, Epidemiology and Hepatology. According to data from OpenAlex, Raphael Mohr has authored 70 papers receiving a total of 942 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 29 papers in Epidemiology and 27 papers in Hepatology. Recurrent topics in Raphael Mohr's work include Liver Disease Diagnosis and Treatment (19 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers) and Hepatocellular Carcinoma Treatment and Prognosis (13 papers). Raphael Mohr is often cited by papers focused on Liver Disease Diagnosis and Treatment (19 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers) and Hepatocellular Carcinoma Treatment and Prognosis (13 papers). Raphael Mohr collaborates with scholars based in Germany, Spain and Denmark. Raphael Mohr's co-authors include Frank Tacke, Christoph Roderburg, Jürgen K. Rockstroh, Ulrich Spengler, Christian P. Strassburg, Maria A. González-Carmona, Jonel Trebicka, Annabelle Vogt, Leona Dold and Tom Luedde and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Raphael Mohr

62 papers receiving 927 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raphael Mohr Germany 18 311 307 290 233 189 70 942
Laurence P. Diggs United States 14 193 0.6× 391 1.3× 99 0.3× 173 0.7× 185 1.0× 37 823
Ka Wing Hong Kong 15 182 0.6× 315 1.0× 304 1.0× 295 1.3× 121 0.6× 54 893
Sandra J. Casak United States 18 109 0.4× 455 1.5× 114 0.4× 215 0.9× 171 0.9× 32 1.0k
Eléonora De Martin France 14 278 0.9× 605 2.0× 400 1.4× 166 0.7× 126 0.7× 47 1.1k
Jason S. Starr United States 14 281 0.9× 643 2.1× 121 0.4× 224 1.0× 143 0.8× 79 1.0k
Mehmet Akce United States 16 205 0.7× 847 2.8× 155 0.5× 255 1.1× 187 1.0× 115 1.2k
Masaru Inagaki Japan 15 111 0.4× 302 1.0× 189 0.7× 155 0.7× 312 1.7× 115 952
Kohei Shigeta Japan 15 117 0.4× 590 1.9× 134 0.5× 210 0.9× 139 0.7× 75 945
H. Raith Germany 11 186 0.6× 207 0.7× 123 0.4× 137 0.6× 233 1.2× 16 732
Takafumi Kumamoto Japan 17 149 0.5× 600 2.0× 473 1.6× 297 1.3× 97 0.5× 78 1.1k

Countries citing papers authored by Raphael Mohr

Since Specialization
Citations

This map shows the geographic impact of Raphael Mohr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raphael Mohr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raphael Mohr more than expected).

Fields of papers citing papers by Raphael Mohr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raphael Mohr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raphael Mohr. The network helps show where Raphael Mohr may publish in the future.

Co-authorship network of co-authors of Raphael Mohr

This figure shows the co-authorship network connecting the top 25 collaborators of Raphael Mohr. A scholar is included among the top collaborators of Raphael Mohr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raphael Mohr. Raphael Mohr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Auer, Timo Alexander, Georg Böning, Uli Fehrenbach, et al.. (2025). CT-guided high-dose-rate brachytherapy ablation of HCC patients with portal vein tumor thrombosis. European Radiology Experimental. 9(1). 16–16.
2.
Bota, Simona, Peter Höfer, Michael Hackl, et al.. (2025). Development of Liver‐Heart Score for Early Detection of Myocardial Contractile Dysfunction in Cirrhosis by Strain Imaging. Liver International. 45(4). e70062–e70062.
3.
Phan, Minh D., Burcin Özdirik, Hilmar Berger, et al.. (2025). Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma. Liver International. 45(6). e70121–e70121. 1 indexed citations
4.
Arnold, Leggy A., Raphael Mohr, Matthäus Felsenstein, et al.. (2024). Extracellular NAD+ response to post-hepatectomy liver failure: bridging preclinical and clinical findings. Communications Biology. 7(1). 991–991.
5.
Demir, Münevver, Alexander Wree, Tom Luedde, et al.. (2023). Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort. Alimentary Pharmacology & Therapeutics. 57(11). 1313–1325. 35 indexed citations
6.
Geisel, Dominik, et al.. (2023). The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma—State of the Art and Future Perspectives. Cancers. 15(1). 301–301. 9 indexed citations
7.
Costa, Frederico, Bertram Wiedenmann, Christoph Roderburg, Raphael Mohr, & Ghassan K. Abou‐Alfa. (2023). Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma. Cancer Medicine. 12(13). 13978–13990. 9 indexed citations
8.
9.
Roderburg, Christoph, et al.. (2023). Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art. Journal of Hepatocellular Carcinoma. Volume 10. 181–191. 12 indexed citations
10.
Auer, Timo Alexander, Federico Collettini, Uwe Pelzer, et al.. (2023). Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma. Cancers. 15(9). 2655–2655. 5 indexed citations
11.
Schulz, Axel, Henrik E. Mei, Raphael Mohr, et al.. (2023). Immune signatures of checkpoint inhibitor-induced autoimmunity—A focus on neurotoxicity. Neuro-Oncology. 26(2). 279–294. 12 indexed citations
12.
Lang, Sonja, Anna Martin, Xinlian Zhang, et al.. (2021). Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy‐proven non‐alcoholic fatty liver disease. Liver International. 41(7). 1576–1591. 22 indexed citations
13.
Özdirik, Burcin, Lynn Jeanette Savic, Raphael Mohr, et al.. (2021). Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma. Medicine. 100(24). e26377–e26377. 14 indexed citations
14.
Mohr, Raphael, Burcin Özdirik, Joeri Lambrecht, et al.. (2021). From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. International Journal of Molecular Sciences. 22(3). 1492–1492. 21 indexed citations
15.
Geisler, Lukas, Raphael Mohr, Joeri Lambrecht, et al.. (2021). The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. International Journal of Molecular Sciences. 22(16). 8569–8569. 13 indexed citations
16.
Gallage, Suchira, María García‐Beccaria, Marta Szydlowska, et al.. (2021). The therapeutic landscape of hepatocellular carcinoma. Med. 2(5). 505–552. 34 indexed citations
17.
Özdirik, Burcin, Raphael Mohr, Lukas Geisler, et al.. (2020). Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study. Journal of Clinical Medicine. 9(9). 2881–2881. 8 indexed citations
18.
Mohr, Raphael, Burcin Özdirik, Alexander Wree, et al.. (2020). In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?. International Journal of Molecular Sciences. 21(14). 4993–4993. 11 indexed citations
19.
Mohr, Raphael, Lukas Geisler, Alexander Wree, et al.. (2020). Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. PLoS ONE. 15(12). e0244504–e0244504. 4 indexed citations
20.
Özdirik, Burcin, Lukas Geisler, Raphael Mohr, et al.. (2020). Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies. Journal of Clinical Medicine. 9(6). 1647–1647. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laurence P. Diggs Breakdown of academic impact, for papers by Ka Wing Breakdown of academic impact, for papers by Sandra J. Casak Breakdown of academic impact, for papers by Eléonora De Martin Breakdown of academic impact, for papers by Jason S. Starr Breakdown of academic impact, for papers by Mehmet Akce Breakdown of academic impact, for papers by Masaru Inagaki Breakdown of academic impact, for papers by Kohei Shigeta Breakdown of academic impact, for papers by H. Raith Breakdown of academic impact, for papers by Takafumi Kumamoto
Rankless by CCL
2026